Australija - engleski - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - trifluridine, quantity: 20 mg; tipiracil hydrochloride, quantity: 9.42 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 8000; titanium dioxide; hypromellose; indigo carmine aluminium lake; iron oxide yellow; carnauba wax; magnesium stearate; lactose monohydrate; iron oxide red; shellac; pregelatinised maize starch - colorectal cancer lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) who have been previously treated with, or are not considered candidates for fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.,gastric cancer lonsurf is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, her2/neu-targeted therapy.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - lurasidone hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: mannitol; croscarmellose sodium; pregelatinised maize starch; magnesium stearate; hypromellose; carnauba wax; titanium dioxide; macrogol 6000 - latuda is indicated for the treatment of schizophrenia in adults and adolescents (aged 13 to 17 years).

Australija - engleski - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; maltodextrin; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg-120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: lactose monohydrate; magnesium stearate; maltodextrin; hypromellose; colloidal anhydrous silica - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg-120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 5 mg; indapamide hemihydrate, quantity: 1.25 mg - tablet, film coated - excipient ingredients: magnesium stearate; macrogol 6000; maltodextrin; sodium starch glycollate type a; colloidal anhydrous silica; lactose monohydrate; colour - treatment of hypertension. treatment should not be initiated with this combination.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 2.5 mg; indapamide hemihydrate, quantity: 0.625 mg - tablet, film coated - excipient ingredients: macrogol 6000; colloidal anhydrous silica; lactose monohydrate; maltodextrin; magnesium stearate; sodium starch glycollate type a; colour - treatment of hypertension.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; magnesium stearate; maltodextrin; hydrophobic colloidal silica anhydrous; macrogol 6000; colour - coversyl is indicated for: the treatment of hypertension; and the treatment of heart failure. in such patients it is recommended that coversyl be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of coversyl has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 5 mg; indapamide hemihydrate, quantity: 1.25 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; macrogol 6000; colloidal anhydrous silica; maltodextrin; magnesium stearate; colour - treatment of hypertension. treatment should not be initiated with this combination.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maltodextrin; sodium starch glycollate; macrogol 6000; hydrophobic colloidal silica anhydrous; colour - prexum is indicated for: the treatment of hypertension; and the treatment of heart failure. in such patients it is recommended that prexum be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of prexum has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - indapamide hemihydrate, quantity: 1.5 mg - tablet, modified release - excipient ingredients: lactose monohydrate; macrogol 6000; hypromellose; magnesium stearate; titanium dioxide; colloidal anhydrous silica; glycerol; povidone - management of essential hypertension. it may be tried as a sole therapeutic agent in the treatment of mild to moderate hypertension. normally, natrilix sr is used as the initial agent in multiple drug regimes.